ReNeuron to present at Royal

RNS Number : 2388B

ReNeuron Group plc

22 October 2009

 



PRESS RELEASE

ReNeuron to present ReN001 stroke programme at Royal Society of Medicine briefing

Guildford, UK, 22 October 2009: ReNeuron Group plc (LSE: RENE.L) announces that it will present its approach to the treatment of disabled stroke patients with its ReN001 stem cell therapy at the Royal Society of Medicine's 10th Medical Innovations Briefing to be held in London on the evening of 27 October 2009. 

The presentation will describe ReNeuron's ReN001 stroke therapy and aspects of the proposed Phase I clinical trial with ReN001, for which UK regulatory and conditional ethical approvals were obtained earlier this year. The briefing will be given by the Principal Investigator for the Phase I trial, Professor Keith Muir, SINAPSE Professor of Clinical Imaging, Division of Clinical Neurosciences at the University of Glasgow, and Dr John Sinden, Chief Scientific Officer of ReNeuron.

The proceedings will be filmed and made available via the websites of ReNeuron and the Royal Society of Medicine in due course.  

Enquiries:

Michael Hunt, Chief Executive Officer Dr John Sinden, Chief Scientific Officer ReNeuron Group plc	[phone]
Jonathan Birt, Susan Quigley Financial Dynamics	[phone]
Simon Leathers  Daniel Stewart & Company plc	[phone]
Alastair Stratton, Tim Graham  Matrix Corporate Capital LLP	[phone]
Carmel Turner Royal Society of Medicine	[phone]

About ReNeuron

ReNeuron is a leading, UK-based stem cell business. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has received regulatory and conditional ethical approvals to commence a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. The Company is developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research. The

Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

 

END

 

 

MSCBDBDGRSDGGCD